Every two minutes, a woman dies from childbirth or pregnancy complications. Stalled maternal mortality rates reflect ...

The skepticism the Duchess of Sussex has received isn’t just about celebrity gossip, it’s a microcosm of how society often ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

Cardiomyopathy is a disease that affects the heart muscle (known as the myocardium). There are different types of cardiomyopathy. Each of these cause damage to the heart muscle, such as enlarging it ...

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 9.71%, which has investors questioning if this is right time to buy ...

Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative gene-therapy strategy ...

The frequency of sudden heart attacks during daily activities like dancing or driving has increased, raising public health ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

Background Apical hypertrophic cardiomyopathy (HCM) is a rare variant of HCM, often considered to have a benign prognosis. This study aimed to compare the clinical characteristics and genetic ...

Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...

Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...